Crystalline and liquid crystalline forms of 25HC3S sodium are described herein. The disclosure includes Forms I, II, III, V, IX, XI, and XIII of 25HC3S sodium and combinations thereof. Pharmaceutical formulations of said forms, or combinations thereof, and methods of treating or preventing disease such as hypercholesterolemia, hypertriglyceridemia, and conditions related to fat accumulation and inflammation (e.g., non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, and atherosclerosis) are further disclosed herein. Methods for preparing 25HC3S are also provided
本文描述了25HC3S
钠的结晶和液晶形式。公开包括25HC3S
钠的I、II、III、V、IX、XI和XIII形式及其组合。还公开了所述形式或其组合的药物配方,以及治疗或预防高
胆固醇血症、高
甘油三酯血症以及与脂肪积累和炎症相关的疾病(例如非
酒精性脂肪肝病(NAFLD)、非
酒精性脂肪性肝炎(NASH)、
酒精性肝炎、急性肾损伤(AKI)、牛皮癣和动脉粥样硬化)的方法也在此公开。还提供了制备25HC3S的方法。